BACKGROUND: An association between GB virus C (GBV-C) and improved outcomes of human immunodeficiency virus (HIV) infection has been reported in HIV-positive individuals with active GBV-C coinfection. This study provides insights into the immune mechanisms underlying the protective role of GBV-C in HIV-infected patients. METHODS: The concentrations of 64 cytokines and chemokines were measured in plasma samples obtained from the Viral Activation Transfusion Study cohort before transfusion and longitudinally from 30 patients positive for both HIV and GBV-C (hereafter, "cases") and 30 patients positive for HIV and negative for GBV-C (hereafter, "controls"). RESULTS: Cases had lower HIV viral loads and higher CD4 T-cell counts than controls after acquisition of GBV-C infection. Most of the modulated cytokines and chemokines were reduced after GBV-C detection, including many proinflammatory cytokines, suggesting an overall antiinflammatory effect of GBV-C in HIV-positive subjects. Most pathways and functions of the measured cytokines were downregulated in cases, except cell death pathways, which were upregulated in various cell subsets in the 3 months after GBV-C detection. CONCLUSIONS: GBV-C has a protective effect, in part through a competition mechanism leading to decreased inflammation and improved HIV disease outcome in cases. Further studies are necessary to establish whether GBV-C may have deleterious effects on the host at the cellular level, including depleting the cells that are the targets of HIV.
RCT Entities:
BACKGROUND: An association between GB virus C (GBV-C) and improved outcomes of human immunodeficiency virus (HIV) infection has been reported in HIV-positive individuals with active GBV-C coinfection. This study provides insights into the immune mechanisms underlying the protective role of GBV-C in HIV-infectedpatients. METHODS: The concentrations of 64 cytokines and chemokines were measured in plasma samples obtained from the Viral Activation Transfusion Study cohort before transfusion and longitudinally from 30 patients positive for both HIV and GBV-C (hereafter, "cases") and 30 patients positive for HIV and negative for GBV-C (hereafter, "controls"). RESULTS: Cases had lower HIV viral loads and higher CD4 T-cell counts than controls after acquisition of GBV-C infection. Most of the modulated cytokines and chemokines were reduced after GBV-C detection, including many proinflammatory cytokines, suggesting an overall antiinflammatory effect of GBV-C in HIV-positive subjects. Most pathways and functions of the measured cytokines were downregulated in cases, except cell death pathways, which were upregulated in various cell subsets in the 3 months after GBV-C detection. CONCLUSIONS:GBV-C has a protective effect, in part through a competition mechanism leading to decreased inflammation and improved HIV disease outcome in cases. Further studies are necessary to establish whether GBV-C may have deleterious effects on the host at the cellular level, including depleting the cells that are the targets of HIV.
Authors: Mel Krajden; Amanda Yu; Heather Braybrook; Agnes S Lai; Annie Mak; Ron Chow; Darrel Cook; Raymond Tellier; Martin Petric; Randy D Gascoyne; Joseph M Connors; Angela R Brooks-Wilson; Richard P Gallagher; John J Spinelli Journal: Int J Cancer Date: 2010-06-15 Impact factor: 7.396
Authors: Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer Journal: J Infect Dis Date: 2012-03-20 Impact factor: 5.226
Authors: Farnaz Vahidnia; Maya Petersen; Jack T Stapleton; George W Rutherford; Michael Busch; Brian Custer Journal: Clin Infect Dis Date: 2012-07-02 Impact factor: 9.079
Authors: Carolynne Schwarze-Zander; Markus Neibecker; Sabrina Othman; Cristina Tural; Bonaventura Clotet; Jason T Blackard; Bernd Kupfer; Guido Luechters; Ray T Chung; Jürgen K Rockstroh; Ulrich Spengler Journal: Antivir Ther Date: 2010
Authors: Maria Teresa Maidana-Giret; Tânia M Silva; Mariana M Sauer; Helena Tomiyama; José Eduardo Levi; Katia C Bassichetto; Anna Nishiya; Ricardo S Diaz; Ester C Sabino; Ricardo Palacios; Esper Georges Kallas Journal: AIDS Date: 2009-11-13 Impact factor: 4.177
Authors: Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton Journal: Br J Haematol Date: 2018-05-29 Impact factor: 6.998
Authors: Adam L Bailey; Michael Lauck; Mariel Mohns; Eric J Peterson; Kerry Beheler; Kevin G Brunner; Kristin Crosno; Andres Mejia; James Mutschler; Matthew Gehrke; Justin Greene; Adam J Ericsen; Andrea Weiler; Gabrielle Lehrer-Brey; Thomas C Friedrich; Samuel D Sibley; Esper G Kallas; Saverio Capuano; Jeffrey Rogers; Tony L Goldberg; Heather A Simmons; David H O'Connor Journal: Sci Transl Med Date: 2015-09-16 Impact factor: 17.956
Authors: Adam L Bailey; Michael Lauck; Ria R Ghai; Chase W Nelson; Katelyn Heimbruch; Austin L Hughes; Tony L Goldberg; Jens H Kuhn; Anna J Jasinska; Nelson B Freimer; Cristian Apetrei; David H O'Connor Journal: J Virol Date: 2016-07-11 Impact factor: 5.103
Authors: Jason T Blackard; Gang Ma; Jeffrey A Welge; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Jack D Sobel; Denise J Jamieson; Caroline C King Journal: J Med Virol Date: 2017-08-28 Impact factor: 2.327
Authors: Angelo Fama; Melissa C Larson; Brian K Link; Thomas M Habermann; Andrew L Feldman; Timothy G Call; Stephen M Ansell; Mark Liebow; Jinhua Xiang; Matthew J Maurer; Susan L Slager; Grzegorz S Nowakowski; Jack T Stapleton; James R Cerhan Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Ashton Harper; Vineetha Vijayakumar; Arthur C Ouwehand; Jessica Ter Haar; David Obis; Jordi Espadaler; Sylvie Binda; Shrilakshmi Desiraju; Richard Day Journal: Front Cell Infect Microbiol Date: 2021-02-12 Impact factor: 6.073